Contrastive Machine Learning to Quantify Hypertensive Multiorgan Damage and Identify New Disease Phenotypes: A Multinational Multimodal Study
Listen to this summary
The authors aimed to develop a novel machine learning approach to quantify multiorgan damage associated with hypertension and identify distinct disease phenotypes. By analyzing data from over 27,000 participants, they created a global organ damage score (HyperScore) and identified six hypertensive disease phenotypes, demonstrating the model's effectiveness in predicting organ-specific disease progression and survival outcomes. This study suggests that machine learning can enhance hypertension assessment and enable personalized risk management strategies.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Circulation
View all →Jul 9, 2026 · Circulation
Exercise Training in High-Risk Populations: A Scientific Statement From the American Heart Association
Jul 8, 2026 · Circulation
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association
Jul 6, 2026 · Circulation
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Jun 29, 2026 · Circulation
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Jun 26, 2026 · Circulation
Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry
Jun 24, 2026 · Circulation
Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association
More in Thoracic Surgery (Cardiothoracic Vascular Surgery)
View all →Jul 10, 2026 · Lancet (London, England)
Advancing the relevance of clinical trials for older patients
Jul 9, 2026 · Lancet (London, England)
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
Jul 9, 2026 · JAMA
Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States
Jul 9, 2026 · Lancet (London, England)
Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations
Jul 9, 2026 · Lancet (London, England)
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial
Jul 8, 2026 · The New England journal of medicine
Meningococcal B Vaccine to Prevent <em>Neisseria gonorrhoeae</em> Infection
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


